According to filings with the U.S. Securities and Exchange Commission, GalenusRx is raising up to $8,030,647.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Jacques Turgeon played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About GalenusRx
Founded in 2023 by a team of internationally recognized healthcare leaders, GalenusRx is revolutionizing medication safety with the power of precision. The companys proprietary platform, APPRAISE, analyzes drug-drug, multi-drug, drug-gene, and drug-disease interactions to provide a unique and comprehensive risk assessment, individualized down to the DNA. Through the Lifesaving InsightsTM consulting service, Precision Clinical Pharmacists deliver tailored recommendations for safer, more effective drug regimens. Together, these solutions directly address polypharmacy and the potential for adverse drug events a leading cause of death in the United States. GalenusRxs deep data analysis also enhances the quality, safety, and efficiency of virtual clinical trials, allowing for biosimulations based on real patient data that dont expose patients to risk. The benefits span from consumers to healthcare providers, insurers, and pharmaceutical companies, with GalenusRxs technology leading the way toward better health outcomes and lower medical costs.

To learn more about GalenusRx, visit http://www.galenusrx.com/
GalenusRx Linkedin Page: https://www.linkedin.com/company/galenusrx/

Contact:
Jacques Turgeon, Chief Executive Officer
407-757-4445

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.